Deal Watch: Purdue Continues Move Away From Opioids With Alivio Deal
In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.
You may also be interested in...
BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Europe’s largest private family-backed biotech adds to its antibody pipeline and its infrastructure in the US with assets from MabVax Therapeutics, in order to pioneer patient-specific immunotherapies for cancer and infections.
As part of efforts to raise cash to pay for its acquisition of Shire, Takeda will sell off selected real estate holdings in Japan, including its Osaka HQ, to a mystery buyer.